|
EP1802193B1
(en)
*
|
2004-10-19 |
2014-04-30 |
Regeneron Pharmaceuticals, Inc. |
Method for generating a mouse homozygous for a genetic modification
|
|
US7740159B2
(en)
*
|
2006-08-02 |
2010-06-22 |
Ethicon Endo-Surgery, Inc. |
Pneumatically powered surgical cutting and fastening instrument with a variable control of the actuating rate of firing with mechanical power assist
|
|
TWI476280B
(zh)
*
|
2008-03-07 |
2015-03-11 |
Regeneron Pharma |
來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
|
|
EP3028565B1
(en)
|
2009-07-08 |
2017-09-27 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US8518392B2
(en)
|
2009-08-14 |
2013-08-27 |
Regeneron Pharmaceuticals, Inc. |
Promoter-regulated differentiation-dependent self-deleting cassette
|
|
EP3417701B1
(en)
*
|
2009-10-06 |
2021-12-15 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice and engraftment
|
|
US8754287B2
(en)
|
2009-12-10 |
2014-06-17 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
EP3336102A3
(en)
|
2009-12-21 |
2018-08-01 |
Regeneron Pharmaceuticals, Inc. |
Humanized fc gamma r mice
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
SMT201900372T1
(it)
|
2010-02-08 |
2019-09-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
WO2011156723A1
(en)
|
2010-06-11 |
2011-12-15 |
Regeneron Pharmaceuticals, Inc. |
Production of fertile xy female animals from xy es cells
|
|
NZ605966A
(en)
|
2010-06-17 |
2015-04-24 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
SI2480676T1
(sl)
|
2010-06-22 |
2016-10-28 |
Regeneron Pharmaceuticals, Inc. |
Hibridna mišja lahka veriga
|
|
RU2580017C2
(ru)
|
2010-07-26 |
2016-04-10 |
Трианни, Инк. |
Трансгенные животные и способы применения
|
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
RU2612903C2
(ru)
|
2010-08-02 |
2017-03-13 |
Ридженерон Фармасьютикалз, Инк. |
Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
|
|
WO2012092284A1
(en)
|
2010-12-27 |
2012-07-05 |
The Jackson Laboratory |
Compositions and methods relating to non-human animals modified to promote production of selected gametes
|
|
RU2577978C2
(ru)
|
2011-02-15 |
2016-03-20 |
Ридженерон Фармасьютикалз, Инк. |
Гуманизированные m-csf мыши
|
|
DK2813573T1
(da)
|
2011-02-25 |
2015-01-12 |
Regeneron Pharma |
ADAM6 mus
|
|
ES2541535T3
(es)
|
2011-05-12 |
2015-07-21 |
Regeneron Pharmaceuticals, Inc. |
Ensayo de liberación de neuropéptido para canales de sodio
|
|
WO2012168399A1
(en)
|
2011-06-08 |
2012-12-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting, treating and modelling hormone resistance
|
|
HUE068728T2
(hu)
|
2011-08-05 |
2025-01-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
EP2757875B2
(en)
|
2011-09-19 |
2023-03-22 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
RU2751240C2
(ru)
|
2011-10-28 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Гуманизированные il-6 и рецептор il-6
|
|
KR102295746B1
(ko)
|
2011-10-28 |
2021-09-01 |
리제너론 파아마슈티컬스, 인크. |
유전자 변형된 주요 조직적합성 복합체 마우스
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
CN104011071B
(zh)
|
2011-10-28 |
2017-11-07 |
瑞泽恩制药公司 |
T细胞受体基因修饰小鼠
|
|
SG10201510056SA
(en)
|
2011-10-28 |
2016-01-28 |
Regeneron Pharma |
Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
US9381518B2
(en)
|
2011-10-31 |
2016-07-05 |
Merck Sharp & Dohme Corp. |
Nano-suspension process
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
MX378871B
(es)
|
2011-12-20 |
2025-03-10 |
Regeneron Pharma |
Ratones con cadena ligera humanizada.
|
|
WO2013096562A1
(en)
|
2011-12-22 |
2013-06-27 |
E. I. Du Pont De Nemours And Company |
Use of the soybean sucrose synthase promoter to increase plant seed lipid content
|
|
PL2809150T3
(pl)
|
2012-02-01 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL
|
|
AU2013204140B2
(en)
|
2012-03-06 |
2016-01-28 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
KR102213535B1
(ko)
|
2012-03-16 |
2021-02-08 |
리제너론 파마슈티칼스 인코포레이티드 |
pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
CA2865644A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
EP3348140B1
(en)
|
2012-03-16 |
2020-12-30 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
JP6275120B2
(ja)
|
2012-04-25 |
2018-02-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
大きい標的化ベクターによるヌクレアーゼ媒介標的化
|
|
EP2858487B1
(en)
|
2012-06-12 |
2019-10-23 |
Regeneron Pharmaceuticals, Inc. |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
|
NZ746089A
(en)
|
2012-09-07 |
2020-05-29 |
Institute For Res In Biomedicine Irb |
Genetically modified non-human animals and methods of use thereof
|
|
ES2748662T3
(es)
|
2012-11-05 |
2020-03-17 |
Institute For Res In Biomedicine Irb |
Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
|
|
CA2900832A1
(en)
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized t-cell co-receptors
|
|
JP6475172B2
(ja)
|
2013-02-20 |
2019-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ラットの遺伝子組換え
|
|
JP6444321B2
(ja)
|
2013-02-22 |
2018-12-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ヒト化主要組織適合性遺伝子複合体を発現するマウス
|
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
|
WO2014164640A1
(en)
|
2013-03-11 |
2014-10-09 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
|
|
AU2014249148B2
(en)
|
2013-03-11 |
2020-04-02 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
|
|
PT3501272T
(pt)
|
2013-03-13 |
2023-03-29 |
Regeneron Pharma |
Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina
|
|
RU2015143108A
(ru)
|
2013-03-13 |
2017-04-20 |
Регенерон Фарматютикалз, Инк. |
Мышь с общей легкой цепью
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
JP6689498B2
(ja)
*
|
2013-04-16 |
2020-04-28 |
イーエムべーアー−インスティツート フューア モレクラー ビオテクノロギー ゲーエムベーハー |
ブラストイド、細胞株に基づく人工胚盤胞
|
|
EP3456831B1
(en)
|
2013-04-16 |
2021-07-14 |
Regeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
IL294443A
(en)
|
2013-08-07 |
2022-09-01 |
Regeneron Pharma |
Lincrna-deficient non-human animals
|
|
KR102150414B1
(ko)
|
2013-09-18 |
2020-09-02 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
|
|
SMT202500280T1
(it)
|
2013-09-23 |
2025-09-12 |
Regeneron Pharma |
Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
|
|
WO2015049517A2
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
NZ719493A
(en)
|
2013-11-07 |
2020-02-28 |
Ozgene Holdings Pty Ltd |
Compositions and methods for producing genetically modified animals
|
|
EP3071024B1
(en)
|
2013-11-19 |
2018-09-05 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized b-cell activating factor gene
|
|
EP3430898A1
(en)
|
2013-11-19 |
2019-01-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized a proliferation-inducing ligand gene
|
|
MX388127B
(es)
|
2013-12-11 |
2025-03-19 |
Regeneron Pharma |
Metodos y composiciones para la modificacion dirigida de un genoma.
|
|
ES2975317T3
(es)
*
|
2013-12-11 |
2024-07-04 |
Regeneron Pharma |
Métodos y composiciones para la modificación dirigida de un genoma
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
RU2016141307A
(ru)
|
2014-03-21 |
2018-04-24 |
Регенерон Фармасьютикалз, Инк. |
Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
|
|
US9795121B2
(en)
|
2014-05-05 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Humanized C3 animals
|
|
NO2785538T3
(enExample)
|
2014-05-07 |
2018-08-04 |
|
|
|
KR102821645B1
(ko)
|
2014-05-19 |
2025-06-19 |
리제너론 파마슈티칼스 인코포레이티드 |
인간 epo를 발현하는 유전자 변형된 비-인간 동물
|
|
BR112016026245A2
(pt)
|
2014-05-30 |
2018-02-20 |
Regeneron Pharma |
?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor?
|
|
BR112016028564A2
(pt)
|
2014-06-06 |
2018-01-30 |
Regeneron Pharma |
método para modificar um locus-alvo em uma célula.
|
|
DK3157956T3
(da)
|
2014-06-19 |
2020-04-27 |
Regeneron Pharma |
Ikke-humane dyr med et humaniseret gen med programmeret celledød 1
|
|
SG10201911411YA
(en)
|
2014-06-26 |
2020-02-27 |
Regeneron Pharma |
Methods and compositions for targeted genetic modifications and methods of use
|
|
KR20170083534A
(ko)
|
2014-09-19 |
2017-07-18 |
리제너론 파마슈티칼스 인코포레이티드 |
키메라 항원 수용체
|
|
CA2963315A1
(en)
|
2014-10-15 |
2016-04-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
|
CA3176380A1
(en)
|
2014-11-21 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
|
BR112017010793A2
(pt)
|
2014-11-24 |
2017-12-26 |
Regeneron Pharma |
animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
|
|
ES2969389T3
(es)
|
2014-12-05 |
2024-05-17 |
Regeneron Pharma |
Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
|
|
EP4399969A3
(en)
|
2014-12-09 |
2024-10-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized cluster of differentiation 274 gene
|
|
BR112017013104A2
(pt)
|
2014-12-19 |
2018-05-15 |
Regeneron Pharma |
métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
|
|
BR112017019620A2
(pt)
|
2015-03-16 |
2018-05-15 |
Regeneron Pharmaceuticals, Inc. |
?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor?
|
|
US11111314B2
(en)
|
2015-03-19 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
AU2016246698B2
(en)
|
2015-04-06 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Humanized T cell mediated immune responses in non-human animals
|
|
SG10202103445QA
(en)
|
2015-04-13 |
2021-05-28 |
Regeneron Pharma |
Humanized sirpa-il15 knockin mice and methods of use thereof
|
|
ES2784360T3
(es)
|
2015-05-29 |
2020-09-24 |
Regeneron Pharma |
Animales no humanos que tienen una interrupción en un locus C9ORF72
|
|
EP3310159B1
(en)
|
2015-06-16 |
2024-10-09 |
The Jackson Laboratory |
Genetically modified mice and methods relating to complement dependent cytotoxicity
|
|
EP3344034A1
(en)
|
2015-09-02 |
2018-07-11 |
Regeneron Pharmaceuticals, Inc. |
Rodent model of prostate cancer
|
|
JP6868615B2
(ja)
|
2015-09-17 |
2021-05-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
繁殖可能なｘｙ雌マウスを生成するための多能性細胞の選択
|
|
PT3376857T
(pt)
|
2015-11-20 |
2021-05-27 |
Regeneron Pharma |
Animais não humanos com um gene humanizado 3 de ativação de linfócitos
|
|
WO2017095939A1
(en)
|
2015-12-03 |
2017-06-08 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
|
US10582702B2
(en)
|
2016-02-04 |
2020-03-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered ANGPTL8 gene
|
|
WO2017136734A1
(en)
|
2016-02-04 |
2017-08-10 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
EP3416479A1
(en)
|
2016-02-16 |
2018-12-26 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a mutant kynureninase gene
|
|
CA3014645C
(en)
|
2016-02-29 |
2022-10-25 |
Regeneron Pharmaceuticals, Inc. |
Rodents having a humanized tmprss gene
|
|
WO2017201476A1
(en)
|
2016-05-20 |
2017-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide rnas
|
|
IL263160B2
(en)
|
2016-06-03 |
2024-01-01 |
Regeneron Pharma |
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
|
|
BR112019001783A2
(pt)
|
2016-07-29 |
2019-05-07 |
Regeneron Pharmaceuticals, Inc. |
mamífero não humano, e, métodos para produzir o mamífero não humano e de triagem de um composto.
|
|
EP4056031A1
(en)
|
2016-08-11 |
2022-09-14 |
The Jackson Laboratory |
Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals
|
|
US10781453B2
(en)
|
2016-09-30 |
2020-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus
|
|
EP3532493B1
(en)
|
2016-10-27 |
2023-04-26 |
The Jackson Laboratory |
Genetically modified mouse model for human hepatocyte xenotransplantation
|
|
JP7458185B2
(ja)
|
2016-11-30 |
2024-03-29 |
ザ ジャクソン ラボラトリー |
改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル
|
|
SG10202109874VA
(en)
|
2017-01-19 |
2021-10-28 |
Open Monoclonal Tech Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
US11064685B2
(en)
|
2017-02-27 |
2021-07-20 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal models of retinoschisis
|
|
WO2018175581A1
(en)
|
2017-03-21 |
2018-09-27 |
The Jackson Laboratory |
A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF
|
|
SG10202112528QA
(en)
|
2017-05-12 |
2021-12-30 |
Jackson Lab |
Nsg mice lacking mhc class i and class ii
|
|
KR20240135035A
(ko)
|
2017-06-27 |
2024-09-10 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 asgr1 유전자좌를 포함하는 비인간 동물
|
|
KR102780441B1
(ko)
|
2017-07-31 |
2025-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
|
|
RU2019143568A
(ru)
|
2017-07-31 |
2021-09-02 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для оценки crispr/cas-индуцированной рекомбинации с экзогенной донорной нуклеиновой кислотой in vivo
|
|
KR20200033259A
(ko)
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
|
|
IL272475B2
(en)
|
2017-08-09 |
2025-05-01 |
Jackson Lab |
Immunodeficient mice expressing interleukin 15
|
|
CN111386039B
(zh)
|
2017-09-29 |
2023-02-28 |
瑞泽恩制药公司 |
经基因修饰的啮齿动物基因组
|
|
EP3585162B1
(en)
|
2017-09-29 |
2023-08-30 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized ttr locus and methods of use
|
|
CN111565566B
(zh)
|
2017-11-10 |
2022-10-21 |
瑞泽恩制药公司 |
包含slc30a8突变的非人动物及使用方法
|
|
JP7361031B2
(ja)
|
2017-11-30 |
2023-10-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
|
|
CN111885915B
(zh)
|
2018-03-19 |
2023-04-28 |
瑞泽恩制药公司 |
使用crispr/cas系统对动物进行转录调制
|
|
SMT202500038T1
(it)
|
2018-03-24 |
2025-03-12 |
Regeneron Pharma |
Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
|
|
KR20250121150A
(ko)
|
2018-03-26 |
2025-08-11 |
리제너론 파마슈티칼스 인코포레이티드 |
치료제를 시험하기 위한 인간화된 설치류
|
|
JP7420730B2
(ja)
|
2018-04-06 |
2024-01-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
|
|
US10463029B1
(en)
|
2018-06-07 |
2019-11-05 |
Regeneron Pharmaceuticals, Inc. |
Rodent model of steel syndrome
|
|
AU2019284762A1
(en)
|
2018-06-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
A rodent model of fibrodysplasia ossificans progressiva
|
|
WO2019246483A1
(en)
|
2018-06-21 |
2019-12-26 |
The Jackson Laboratory |
Genetically modified mouse models of alzheimer's disease
|
|
HUE067361T2
(hu)
|
2018-07-16 |
2024-10-28 |
Regeneron Pharma |
Ditra betegség rágcsáló modelljei és alkalmazásaik
|
|
ES2974200T3
(es)
|
2018-09-13 |
2024-06-26 |
Regeneron Pharma |
Rata nuligénica para el gen del factor H del complemento como modelo de glomerulopatía C3
|
|
KR20210104744A
(ko)
|
2018-12-18 |
2021-08-25 |
리제너론 파마슈티칼스 인코포레이티드 |
렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
|
|
KR20210105914A
(ko)
|
2018-12-20 |
2021-08-27 |
리제너론 파마슈티칼스 인코포레이티드 |
뉴클레아제-매개 반복부 팽창
|
|
US11470828B2
(en)
|
2019-01-17 |
2022-10-18 |
Regeneran Pharmaceuticals, Inc. |
Rodent model of mood disorders
|
|
WO2020152607A1
(en)
|
2019-01-22 |
2020-07-30 |
St. Jude Children's Research Hospital |
Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
|
|
EP3927153A1
(en)
|
2019-02-22 |
2021-12-29 |
Regeneron Pharmaceuticals, Inc. |
Rodents having genetically modified sodium channels and methods of use thereof
|
|
SG11202109407XA
(en)
|
2019-03-15 |
2021-09-29 |
Regeneron Pharma |
A loss of function rodent model of solute carrier 39 member 5
|
|
AU2020253532B2
(en)
|
2019-04-04 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
|
PH12021552675A1
(en)
|
2019-05-13 |
2022-07-04 |
Regeneron Pharma |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
|
WO2020247452A1
(en)
|
2019-06-04 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
CA3136478A1
(en)
|
2019-06-05 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
|
SG11202111256XA
(en)
|
2019-06-07 |
2021-11-29 |
Regeneron Pharma |
Non-human animals comprising a humanized albumin locus
|
|
PH12021552903A1
(en)
|
2019-06-11 |
2022-04-04 |
Regeneron Pharma |
Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
|
|
WO2020264339A1
(en)
|
2019-06-27 |
2020-12-30 |
Regeneron Pharmaceuticals, Inc. |
Modeling tdp-43 proteinopathy
|
|
CA3153141A1
(en)
|
2019-10-03 |
2021-04-08 |
Regeneron Pharmaceuticals, Inc. |
A crnn loss of function rodent model
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
BR112022011417A2
(pt)
|
2019-12-13 |
2022-08-30 |
Alnylam Pharmaceuticals Inc |
Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
|
|
JP2023511626A
(ja)
|
2020-01-28 |
2023-03-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｐｎｐｌａ３遺伝子座を含む非ヒト動物および使用方法
|
|
WO2021158883A1
(en)
|
2020-02-07 |
2021-08-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
|
IL295080A
(en)
|
2020-03-04 |
2022-09-01 |
Regeneron Pharma |
A rodent model of b4galt1-mediated functions
|
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
JP7765403B2
(ja)
|
2020-04-21 |
2025-11-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物
|
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
|
WO2021263146A2
(en)
|
2020-06-26 |
2021-12-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ace2 locus
|
|
EP4221496A1
(en)
|
2020-10-01 |
2023-08-09 |
Regeneron Pharmaceuticals, Inc. |
Rodent animals expressing human cr1
|
|
EP4262373A1
(en)
|
2020-12-16 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized fc alpha receptors
|
|
CN116802200A
(zh)
|
2020-12-21 |
2023-09-22 |
瑞泽恩制药公司 |
具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物
|
|
IL307238A
(en)
|
2021-03-31 |
2023-11-01 |
Regeneron Pharma |
Transgenic mice containing human components of the cellular immune system with an enhanced diversity of the TCRB repertoire
|
|
WO2023081847A1
(en)
|
2021-11-04 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a modified cacng1 locus
|
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
|
US20250049006A1
(en)
|
2021-12-20 |
2025-02-13 |
C/O Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
|
EP4475671A1
(en)
|
2022-02-07 |
2024-12-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
CA3242729A1
(en)
|
2022-02-11 |
2023-08-17 |
Regeneron Pharma |
Compositions and methods for screening 4r tau targeting agents
|
|
WO2023212560A1
(en)
|
2022-04-26 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
A rodent model of fibrodysplasia ossificans progressiva
|
|
WO2023235677A1
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
|
US20230417899A1
(en)
|
2022-06-27 |
2023-12-28 |
Oshkosh Corporation |
Position tracking for a lift device
|
|
WO2024020057A1
(en)
|
2022-07-19 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified animal model and its use to model the human immune system
|
|
KR20250048010A
(ko)
|
2022-07-29 |
2025-04-07 |
리제너론 파마슈티칼스 인코포레이티드 |
변형된 트랜스페린 수용체 좌위를 포함하는 비-인간 동물
|
|
CA3261296A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharma |
TDP-43 VARIANTS RESISTANT TO AGGREGATION
|
|
EP4590120A1
(en)
|
2022-09-22 |
2025-07-30 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice expressing components of human cellular immune system
|
|
WO2024073679A1
(en)
|
2022-09-29 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
EP4658066A1
(en)
|
2023-02-01 |
2025-12-10 |
Regeneron Pharmaceuticals, Inc. |
Animals comprising a modified klhdc7b locus
|
|
KR20250155054A
(ko)
|
2023-03-13 |
2025-10-29 |
리제너론 파마슈티칼스 인코포레이티드 |
흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
|
|
CN116445396B
(zh)
*
|
2023-04-07 |
2025-03-25 |
中国农业大学 |
一种wnt2用于提高体外受精胚胎发育效率和质量的新用途
|
|
WO2024259354A1
(en)
|
2023-06-16 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025006963A1
(en)
|
2023-06-30 |
2025-01-02 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for increasing homology-directed repair
|
|
WO2025106736A2
(en)
|
2023-11-15 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
|
|
WO2025122669A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized complement factor b gene
|
|
WO2025122754A1
(en)
|
2023-12-07 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Gaa knockout non-human animals
|
|
US20250255282A1
(en)
|
2024-02-08 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025212991A1
(en)
|
2024-04-05 |
2025-10-09 |
Regeneron Pharmaceuticals, Inc. |
Rodent models of disease
|
|
WO2025226695A1
(en)
|
2024-04-23 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|